HERS (Heart and Estrogen/Progestin Replacement Study)

Herrington DM, Vittinghoff E, Lin F, et al, for the HERS Study Group. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). Circulation 2002; 105: 2962-2967. Hlatky MA, Boothroyd D, Vittinghoff E, Sharp P, Whooley MA, for the Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/ Progestin Replacement Study (HERS) trial. JAMA 2002; 287: 591-597. Hsia J, Simon JA, Lin F, et al. Peripheral arterial disease in randomized trial of estrogen with progestin in women with coronary heart disease: the Heart and Estrogen/Progestin Replacement Study. Circulation 2000; 102: 2228-2232. Hulley S, Grady D, Bush T, et al, for the Heart and Estrogen/ progestin Replacement Study (HERS) Research Group.

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605-613. Simon JA, Hsia J, Cauley JA, et al. Postmenopausal hormone therapy and risk of stroke: the Heart and Estrogenprogestin Replacement Study (HERS). Circulation 2001; 103: 638-642.

HERS II (Heart and Estrogen/Progestin Replacement Study)

Grady D, Herrington D, Bittner V, et al, for the HERS Research Group.

Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). JAMA 2002; 288: 49-57. Hulley S, Furberg C, Barrett-Connor E, et al, for the HERS Research Group. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/ Progestin Replacement Study follow-up (HERS II). JAMA 2002; 288: 58-66.

WEST (Women^,s Estrogen for Stroke Trial)

Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001; 345: 1243-1249.

Nurses^, Health Study

Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000; 133: 933- 941. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997; 336:

1769-1775. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 335: 453-461.

HOPE (Women^,s Health, Osteoporosis, Progestin, Estrogen trial)

Archer DF, Dorin M, Lewis V, Schneider DL, Pickar JH. Effects of lower doses of conjugated equine estrogens and medroxy progesterone acetate on endometrial bleeding. Fertil Steril 2001; 75: 1080-1087. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 2002; 287: 2668-2676. Lobo RA, Bush T, Carr BR, Pickar JH. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertil Steril 2001; 76: 13-24. Pickar JH, Yeh I, Wheeler JE, Cunnane MF, Speroff L. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001; 76: 25-31. Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar JH. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001; 75: 1065-1079.

ERA (Estrogen Replacement and Atherosclerosis trial)

Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronaryartery atherosclerosis. N Engl J Med 2000; 343: 522-529.

EPAT (Estrogen in the Prevention of Atherosclerosis Trial)

Hodis HN, Mack WJ, Lobo RA, et al, for Estrogen in the Prevention of Atherosclerosis Trial Research Group. Estrogen in the prevention of atherosclerosis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001; 135: 939-953.

MORE (Multiple Outcomes of Raloxifene Evaluation)

Barrett-Connor E, Grady D, Sashegyi A, et al, for the MORE Investigators (Multiple Outcomes of Raloxifene Evaluation).

Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002; 287: 847-857. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation [erratum in: Breast Cancer Res Treat 2001; 67: 191]. Breast Cancer Res Treat 2001; 65: 125-134. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation [erratum in: JAMA 1999; 282: 2124]. JAMA 1999; 281: 2189-2197. Delmas PD, Ensrud KE, Adachi JD, et al, for the Multiple Outcomes of Raloxifene Evaluation Investigators. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002; 87: 3609-3617.

PEPI (Postmenopausal Estrogen/Progestin Interventions study)

Barrett-Connor E, Slone S, Greendale G, et al. The Postmenopausal Estrogen/Progestin Interventions Study: primary outcomes in adherent women. Maturitas 1997; 27: 261- Greendale GA, Espeland M, Slone S, Marcus R, Barrett- Connor E, for the PEPI Safety Follow-up Study (PSFS) Investigators. Bone mass response to discontinuation of long-term hormone replacement therapy: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) safety follow-up study. Arch Intern Med 2002; 162: 665-672. Greendale GA, Wells B, Marcus R, Barrett-Connor E, for the Postmenopausal Estrogen/Progestin Interventions trial investigators. How many women lose bone mineral density while taking hormone replacement therapy? Results from the Postmenopausal Estrogen/Progestin Interventions trial. Arch Intern Med 2000; 160: 3065-3071. The Writing Group for the PEPI trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/ Progestin Interventions (PEPI) Trial [erratum in: JAMA 1995; 274: 1676]. JAMA 1995; 273: 199-208. The Writing Group for the PEPI trial. Effects of hormone therapy on bone mineral density: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA 1996; 276: 1389-1396.

SWAN (Study of Women^,s Health Across the Nation)

Huang M-H, Schocken M, Block G, et al. Variation in nutrient intakes by ethnicity: results from the Study of Women^,s Health Across the Nation (SWAN). Menopause 2002; 9:

309-319.

Qué es la NAMS

La NAMS es una organización líder norteamericana sin ánimo de lucro dedicada a la promoción de la salud de la mujer en la edad adulta y más allá a través del entendimiento de la menopausia. La sociedad reúne en forma única miembros de actividad multidisciplinaria con más de 2.000 afiliados que incluyen expertos en medicina, enfermería, sociología, psicología, antropología, farmacia, epidemiología, nutrición y ciencias básicas.